Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Preferred Stock Liabilities: 2019-2020

Historic Preferred Stock Liabilities for Lyell Immunopharma (LYEL) over the last 1 years, with Dec 2020 value amounting to $1.0 billion.

  • Lyell Immunopharma's Preferred Stock Liabilities rose 94.73% to $1.0 billion in Q4 2020 from the same period last year, while for Dec 2020 it was $1.0 billion, marking a year-over-year increase of 94.73%. This contributed to the annual value of $1.0 billion for FY2020, which is 94.73% up from last year.
  • Per Lyell Immunopharma's latest filing, its Preferred Stock Liabilities stood at $1.0 billion for Q4 2020, which was down 0.00% from $1.0 billion recorded in Q3 2020.
  • Lyell Immunopharma's 5-year Preferred Stock Liabilities high stood at $1.0 billion for Q2 2020, and its period low was $519.2 million during Q4 2019.
  • In the last 2 years, Lyell Immunopharma's Preferred Stock Liabilities had a median value of $1.0 billion in 2020 and averaged $888.0 million.
  • Data for Lyell Immunopharma's Preferred Stock Liabilities shows a peak YoY soared of 94.73% (in 2020) over the last 5 years.
  • Lyell Immunopharma's Preferred Stock Liabilities (Quarterly) stood at $519.2 million in 2019, then skyrocketed by 94.73% to $1.0 billion in 2020.
  • Its Preferred Stock Liabilities stands at $1.0 billion for Q4 2020, versus $1.0 billion for Q3 2020 and $1.0 billion for Q2 2020.